Oxaliplatin-Induced Evans Syndrome: A Possible Dual Mechanism
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Oxaliplatin-Induced Evans Syndrome: A Possible Dual Mechanism |
| Type de publication | Journal Article |
| Year of Publication | 2020 |
| Auteurs | Rousseau C, Nguyen TNgoc, Rebibou JMichel, Bastie JNoel, Audia S, Darut-Jouve A, Legendre M |
| Journal | CLINICAL COLORECTAL CANCER |
| Volume | 19 |
| Pagination | 57-60 |
| Date Published | MAR |
| Type of Article | Editorial Material |
| ISSN | 1533-0028 |
| Mots-clés | Acute kidney injury, Drug dependent antibody, Hemolysis, Nonimmunologic protein adsorption (NIPA), Plasma exchange |
| Résumé | Clinical Practice Points Oxaliplatin is recommended for the treatment of stage II and III colorectal cancer. Most reported adverse effects for oxaliplatin are mild and include paresthesia (2%-12%), diarrhea (11.5%-19%), and vomiting (4.1%-6%). Severe anemia, thrombocytopenia, or Evans syndrome are rarely reported adverse effects for oxaliplatin. To our knowledge, this is the first reported case of Evans syndrome complicated by severe acute tubular necrosis associated with oxaliplatin-induced antibodies and probable nonimmunologic protein adsorption detected with the immune complex method. (C) 2019 Elsevier Inc. All rights reserved. |
| DOI | 10.1016/j.clcc.2019.11.001 |